CAR-T cell therapy

Anixa Biosciences, Inc. (NASDAQ: ANIX) is a clinical-stage biotechnology company headquartered in San Jose, California, developing immune-based therapies to treat and prevent cancer. It has two clinical programs: an FSHR-targeted CAR-T therapy (lira-cel) for ovarian cancer in Phase 1 dose escalation, and an alpha-lactalbumin-targeted breast cancer vaccine that has completed Phase 1 and is preparing for Phase 2. Programs are developed with institutions including Cleveland Clinic, Moffitt Cancer Center, The Wistar Institute, the National Cancer Institute,

Read more

cancer vaccine developmentclinical stage drug development